. Author manuscript; available in PMC: 2019 Aug 1.

Published in final edited form as: Pediatr Blood Cancer. 2018 Apr 25;65(8):e27077. doi: 10.1002/pbc.27077

Table 4.

Pharmacodynamic Markers Change from Baseline

Biomarker	Study day	Median change	p-value^ˆ
AXL^*	21	2383.16 1823.11 32.72	0.011 0.004 <0.001
AXL^*	28 21
CA9^*	28 21
CA9^*	28	35.52	<0.001
PIGF^*	21	40.59	<0.001
PIGF^*	28	41.41	<0.001
OPN^*	21	−18.41	0.008
OPN^*	28	−21.02	0.018
TIMP-1^*	21	−42.13	<0.001
TIMP-1^*	28	−28.13	<0.001
VEGFR2^*	21	−1581.01	<0.001
VEGFR2^*	28	−1992.72	<0.001
cMET	21	15.61	0.173
cMET	28	14.33	0.111
EPO	21	2.77	0.524
EPO	28	6.46	0.119
HGF	21	−144.25	0.077
HGF	28	−123.01	0.650
IL-6	21	0.00	1
IL-6	28	0.00	1

Significant change from baseline

^ˆ

P-values testing the null hypothesis that there is a change in the biomarker level versus baseline using Wilcoxon signed rank test and adjusted for multiple comparisons using the Bonferroni correction.